The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1
Open accessAbstract
Aberrant glycosylation of IgA1 plays an essential role in the pathogenesis of IgA nephropathy. This abnormality is manifested by a deficiency of galactose in the hinge-region O-linked glycans of IgA1. Biosynthesis of these glycans occurs in a stepwise fashion beginning with the addition of N-acetylgalactosamine by the enzyme N-acetylgalactosaminyltransferase 2 and continuing with the addition of either galactose by beta1,3-galactosyltransferase or a terminal sialic acid by a N-acetylgalactosamine-specific alpha2,6-sialyltransferase. To identify the molecular basis for the aberrant IgA glycosylation, we established EBV-immortalized IgA1-producing cells from peripheral blood cells of patients with IgA nephropathy. The secreted IgA1 was mostly polymeric and had galactose-deficient O-linked glycans, characterized by a terminal or sialylated N-acetylgalactosamine. As controls, we showed that EBV-immortalized cells from patients with lupus nephritis and healthy individuals did not produce IgA with the defective galactosylation pattern. Analysis of the biosynthetic pathways in cloned EBV-immortalized cells from patients with IgA nephropathy indicated a decrease in beta1,3-galactosyltransferase activity and an increase in N-acetylgalactosamine-specific alpha2,6-sialyltransferase activity. Also, expression of beta1,3-galactosyltransferase was significantly lower, and that of N-acetylgalactosamine-specific alpha2,6-sialyltransferase was significantly higher than the expression of these genes in the control cells. Thus, our data suggest that premature sialylation likely contributes to the aberrant IgA1 glycosylation in IgA nephropathy and may represent a new therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tomana, M., Novak, J., Julian, B. A., Matousovic, K., Konecny, K., & Mestecky, J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5535 · Cited by 498
Self-citationJu, T., & Cummings, R. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.262438199 · Cited by 487
Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels
Moldoveanu, Z., Wyatt, R. J., Lee, J. Y., Tomana, M., Julian, B. A., Mestecky, J., Huang, W.-Q., Anreddy, S. R., Hall, S., Hastings, M. C., et al. (2007) · Kidney International · doi:10.1038/sj.ki.5002185 · Cited by 422
Self-citationBarratt, J., & Feehally, J. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005020134 · Cited by 386
Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy
Hiki, Y., Odani, H., Takahashi, M., Yasuda, Y., Nishimoto, A., Iwase, H., Shinzato, T., Kobayashi, Y., & Maeda, K. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00591.x · Cited by 378
Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG
Tomana, M., Matoušovic, K., Julian, B. A., Radl, J., Konecný, K., & Mestecky, J. (1997) · Kidney International · doi:10.1038/ki.1997.361 · Cited by 341
Self-citationMesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: Observations in three patients
Allen, A. C., Bailey, E. M., Brenchley, P. E., Buck, K., Barratt, J., & Feehally, J. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.060003969.x · Cited by 311
Priatel, J. J., Chui, D., Hiraoka, N., Simmons, C. J. T., Richardson, K. B., Page, D. M., Fukuda, M., Varki, N. M., & Marth, J. D. (2000) · Immunity · doi:10.1016/s1074-7613(00)80180-6 · Cited by 299
Cloning and Expression of Human Core 1 β1,3-Galactosyltransferase
Ju, T., Brewer, K., D'Souza, A., Cummings, R. D., & Canfield, W. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109060200 · Cited by 290
Chaperone mutation in Tn syndrome
Ju, T., & Cummings, R. D. (2005) · Nature · doi:10.1038/4371252a · Cited by 271
Cited by
Glycosylation in health and disease
Reily, C., Stewart, T. J., Renfrow, M. B., & Novak, J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0129-4 · Cited by 2,075
Sialic acids in human health and disease
Varki, A. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.06.002 · Cited by 999
The Pathophysiology of IgA Nephropathy
Suzuki, H., Kiryluk, K., Novak, J., Moldoveanu, Z., Herr, A. B., Renfrow, M. B., Wyatt, R. J., Scolari, F., Mestecky, J., Gharavi, A. G., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011050464 · Cited by 910
Self-citationThe immune system and kidney disease: basic concepts and clinical implications
Kurts, C., Panzer, U., Anders, H.-J., & Rees, A. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3523 · Cited by 696
Lai, K. N., Tang, S. C. W., Schena, F. P., Novak, J., Tomino, Y., Fogo, A. B., & Glassock, R. J. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.1 · Cited by 508
Self-citationSuzuki, H., Fan, R., Zhang, Z., Brown, R., Hall, S., Julian, B. A., Chatham, W. W., Suzuki, Y., Wyatt, R. J., Moldoveanu, Z., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38468 · Cited by 450
Self-citationThe Mesangial Cell Revisited: No Cell Is an Island
Schlo[Combining Diaeresis]ndorff, D., & Banas, B. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008050549 · Cited by 408
The Tn Antigen—Structural Simplicity and Biological Complexity
Ju, T., Otto, V. I., & Cummings, R. D. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201002313 · Cited by 363
New developments in the genetics, pathogenesis, and therapy of IgA nephropathy
Magistroni, R., D’Agati, V. D., Appel, G. B., & Kiryluk, K. (2015) · Kidney International · doi:10.1038/ki.2015.252 · Cited by 302
Lafayette, R. A., Canetta, P. A., Rovin, B. H., Appel, G. B., Novak, J., Nath, K. A., Sethi, S., Tumlin, J. A., Mehta, K., Hogan, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060640 · Cited by 300
Self-citationAutoantibodies Targeting Galactose-Deficient IgA1 Associate with Progression of IgA Nephropathy
Berthoux, F., Suzuki, H., Thibaudin, L., Yanagawa, H., Maillard, N., Mariat, C., Tomino, Y., Julian, B. A., & Novak, J. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012010053 · Cited by 272
Self-citationKiryluk, K., Moldoveanu, Z., Sanders, J. T., Eison, T. M., Suzuki, H., Julian, B. A., Novak, J., Gharavi, A. G., & Wyatt, R. J. (2011) · Kidney International · doi:10.1038/ki.2011.16 · Cited by 266
Self-citationA Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
Mathur, M., Barratt, J., Chacko, B., Chan, T. M., Kooienga, L., Oh, K.-H., Sahay, M., Suzuki, Y., Wong, M. G., Yarbrough, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2305635 · Cited by 239
The pathogenesis of IgA nephropathy and implications for treatment
Cheung, C. K., Alexander, S., Reich, H. N., Selvaskandan, H., Zhang, H., & Barratt, J. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00885-3 · Cited by 222
Metadata
- Authors
- Suzuki, H., Moldoveanu, Z., Hall, S., Brown, R., Vu, H. L., Novak, L., Julian, B. A., Tomana, M., Wyatt, R. J., Edberg, J. C., Alarcón, G. S., Kimberly, R. P., Tomino, Y., Mestecky, J., & Novak, J.
- Venue
- Journal of Clinical Investigation
- Published
- 2008-01-02
- Volume
- 118
- Issue
- 2
- Pages
- 629-39
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2119832679
- Cited by
- 277
- References
- 38
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.